Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol

Archives of General Psychiatry

Volumn 57, Issue 3, 2000, Pages 249-258

  Purdon, Scot E ^a,g   Jones, Barry D W ^b,c   Stip, Emanuel ^d   Labelle, Alan ^e   Addington, Don ^f   David, Stacy R ^c   Breier, Alan ^c   Tollefson, Gary D ^c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c ELI LILLY AND COMPANY   (United States)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e ROYAL OTTAWA HOSPITAL   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

^g ALBERTA HOSPITAL EDMONTON   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; ATTENTION; CLINICAL TRIAL; COGNITIVE DEFECT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; QUALITY OF LIFE; RECALL; SCHIZOPHRENIA; VERBAL BEHAVIOR;

EID: 0034095251     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.57.3.249     Document Type: Article

References (57)

1. Flor-Henry P, Yeudall LT. Neuropsychological investigations of schizophrenia and manic-depressive psychoses. In: Gruzelier J, Flor-Henry P, eds. Hemisphere Asymmetries of Function in Psychopathology. Amsterdam, the Netherlands: Elsevier/ North-Holland Biomedical Press; 1979:341-362.
2. Kolb B, Whishaw IQ. Performance of schizophrenic patients on tests sensitive to left or right frontal, temporal, or parietal function in neurological patients. J Nerv Ment Dis. 1983;171:435-443.
3. Palmer BW, Heaton RK, Paulsen JS, Kuck J, Braff D, Harris MJ, Zisook S, Jeste DV. Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology. 1997;11:437-446.
4. Bilder RM. Neurocognitive impairment in schizophrenia and how it affects treatment options. Can J Psychiatry. 1997;42:255-264.
5. Bilder RM, Bogerts B, Ashtari M, Wu H, Alvir JM, Jody D, Reiter G, Bell L. Lieberman JA. Anterior hippocampal volume reductions predict frontal lobe dysfunction in first episode schizophrenia. Schizophr Res. 1995;17:47-58.
6. Bilder RM, Turkel E, Lipschutz-Broch L, Lieberman JA. Antipsychotic medication effects on neuropsychological functions. Psychopharmacol Bull. 1992;28: 353-366.
7. Hoff AL, Riordan H, O'Donnell DW, Morris L, DeLisi LE. Neuropsychological functioning of first-episode schizophreniform patients. Am J Psychiatry. 1992;149: 898-903.
8. Jones P, Rodgers B, Murray R, Marmot M. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet. 1994;344:1398-1402.
9. Rubin P, Holm A, Moller-Madsen S, Videbech P, Hertel C, Povlsen UJ, Hemmingsen R. Neuropsychological deficit in newly diagnosed patients with schizophrenia or schizophreniform disorder. Acta Psychiatr Scand. 1995;92:35-43.
10. Brekke JS, Raine A, Ansel M, Lencz T, Bird L. Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia. Schizophr Bull. 1997;23:19-28.
11. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321-330.
12. Jaeger J, Douglas E. Neuropsychiatric rehabilitation for persistent mental illness. Psychiatr Q. 1992;63:71-94.
13. Cassens G, Inglis AK, Appelbaum PS, Gutheil TG. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull. 1990; 16:477-499.
14. Medalia A, Gold J, Merriam A. The effects of neuroleptics on neuropsychological test results in schizophrenia. Arch Clin Neurol. 1988;3:249-271.
15. Spohn HE, Strauss ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol. 1989;98:367-380.
16. Crow TJ. Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry. 1980;137:383-386.
17. Crow TJ, Frith CD, Johnstone EC, Owens DG. Schizophrenia and cerebral atrophy. Lancet 1980;1:1129-1130.
18. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry. 1993;34:702-712.
19. Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry. 1994;55(suppl B):82-87.
20. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry. 1994;36:717-725.
21. Purdon SE, Lit W, Labelle A, Jones BD. Risperidone in the treatment of pervasive developmental disorder. Can J Psychiatry. 1994;39:400-405.
22. Rossi A, Mancini F, Stratta P, Mattel P, Gismondi R, Pozzi F, Casacchia M. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatr Scand. 1997;95:40-43.
23. Stip E, Lussier I. The effect of risperidone on cognition in patients with schizophrenia. Can J Psychiatry 1996;41(suppl):S35-S40.
24. Green MF, Marshall BDJ, Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry. 1997;154:799-804.
25. Volonte M, Monferini E, Cerutti M, Fodritto F, Borsini F. BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J Neurochem. 1997;69:182-190.
26. Robertson GS, Fibiger HC. Effects of olanzapine on regional C-Fos expression in rat forebrain. Neuropsychopharmacology. 1996;14:105-110.
27. Bakshi VP, Geyer MA. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology. 1995;122:198-201.
28. Swerdlow NR, Bakshi V, Geyer MA. Seroquel restores sensorimotor gating in phencyclidine-treated rats. J Pharmacol Exp Ther. 1996;279:1290-1299.
29. Purdon SE. Olanzapine and models of cognition. In: Tran PV, Bymaster F, Tye N, Herrera J, Breier A, Tollefson GD, eds. Olanzapine (Zyprexa): A Novel Antipsychotic. Baltimore, Md: Williams & Wilkins; 2000.
30. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems Inc; 1992.
31. Chouinard G, Jones B, Remington G, Bloom, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993;13:25-40.
32. Dunn LM. Peabody Picture Vocabulary Test-Revised. Circle Pines, Minn: American Guidance Service; 1981.
33. Purdon SE. Cognitive improvement in schizophrenia with novel antipsychotic medications. Schizophr Res. 1999;35:54-64.
34. Halstead WC. Brain and Intelligence. Chicago, III: University of Chicago Press; 1947.
35. Reitan RM. Manual for the Administration of Neuropsychological Test Batteries for Adults and Children. Tucson, Ariz: Neuropsychology Press; 1979.
36. Bornstein RA. Normative data on selected neuropsychological measures from a nonclinical sample. J Clin Psychol. 1985;41:651-659.
37. Klove H. Clinical neuropsychology. In: Forster FM, ed. The Medical Clinics of North America. New York, NY: Sanders; 1963.
38. Klove H, Matthews CG. Neuropsychological studies of patients with epilepsy. In: Reitan RM, Davison LA, eds. Clinical Neuropsychology. Washington, DC: Hemisphere; 1964.
39. Ruff RM, Parker SB. Gender-and age-specific changes in motor speed and eye-hand coordination in adults: normative values for the Finger Tapping and Grooved Pegboard tests. Percept Mot Skills. 1993;76:1219-1230.
40. Wechsler D Wechsler Memory Scale-Revised. San Antonio, Tex: The Psychological Corporation; 1981.
41. Lezak M. Neuropsychological Assessment. 3rd ed. New York, NY: Oxford University Press; 1995.
42. Wechsler D. Wechsler Adult Intelligence Scale-Revised. San Antonio, Tex: The Psychological Corporation; 1981.
43. Jones-Gotman M, Milner B. Design fluency: the invention of nonsense drawings after focal cortical lesions. Neuropsychologia. 1977;15:653-674.
44. Woodward JL, Axelrod BN, Henry R. Interrater reliability of scoring parameters for the design fluency test. Neuropsychology. 1992;6:173-178.
45. Hooper HE. The Hooper Visual Organization Test. Beverly Hills, Calif: Western Psychological Services; 1948.
46. Rey A. L'examen psychologique dans les cas d'encephalopathie traumalique. Arch Psychol. 1941;28:286-340.
47. Taylor LB. Psychological assessment of neurosurgical patients. In: Rasmussen T, Marino R, eds. Functional Neurosurgery. New York, NY: Raven Press; 1979.
48. Meyers JE, Meyers KR. Rey Complex Figure Test under four different administration procedures. Clin Neuropsychol. 1995;9:63-67.
49. Heaton RK. A Manual for the Wisconsin Card Sorting Test. Odessa, Fla: Psychological Assessment Resources Inc; 1981.
50. Geffen GM, Butterworth P, Geffen LB. Test-retest reliability of a new form of the Auditory Verbal Learning Test (AVLT). Arch Clin Neuropsychol. 1994;9:303-316.
51. Rey A. L'examen clinique en psychologie. Paris, France: Presses Universitaites de France; 1964.
52. Spreen O, Strauss E. A Compendium of Neuropsychological Tests. New York, NY: Oxford University Press; 1991.
53. Green P, Kramer E. Auditory Comprehension Tests. Edmonton, Alberta: Auditory Comprehension Tests Ltd; 1983.
54. Wechsler D. A standardized memory scale for clinical use. J Psychol. 1945;19: 87-95.
55. Wechsler D, Stone LP. The Wechsler Memory Scale. New York, NY: Psychological Corporation; 1985.
56. Frith CD. Schizophrenia, memory, and anticholinergic drugs. J Abnorm Psychol. 1984:93:339-341.
57. Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, Stafiniak P, Gur RC. Neuropsychological deficits in neuroleptic naïve patients with first-episode schizophrenia. Arch Gen Psychiatry. 1994;51:124-131.